Efficacy and Safety of Apremilast in Patients With Genital Psoriasis: Results From the Phase 3, Randomized, Placebo-Controlled, Double-blind DISCREET Study

Main Article Content

Joseph Merola
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Lawrence Parish
Parish Dermatology, Philadelphia, PA, USA

Lyn Guenther
Guenther Research Inc., London, ON, Canada

Charles Lynde
Lynde Institute for Dermatology, Markham, ON, Canada

Jean-Philippe Lacour
CHU de Nice - Hôpital l'Archet, Nice, France

Petra Staubach
Department of Dermatology, University Medical Center, Mainz, Germany

Sue Cheng
Amgen Inc., Thousand Oaks, CA, USA

Shauna Jardon
Amgen Inc., Thousand Oaks, CA, USA

Maria Paris
Amgen Inc., Thousand Oaks, CA, USA

Mindy Chen
Amgen Inc., Thousand Oaks, CA, USA

Kim Papp
K Papp Clinical Research, Waterloo, ON, Canada

Keywords

Apremilast, Genital Psoriasis

References

1. Ryan C, et al. J Am Acad Dermatol. 2015;72:978-983.

2. Meeuwis KAP, et al. J Dermatol Treat. 2018;29:754-760.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.110

Article Details

How to Cite
Merola, J., Parish, L., Guenther, L. ., Lynde, C. ., Lacour, J.-P. ., Staubach, P. ., Cheng, S., Jardon, S., Paris, M. ., Chen, M. ., & Papp, K. . (2023). Efficacy and Safety of Apremilast in Patients With Genital Psoriasis: Results From the Phase 3, Randomized, Placebo-Controlled, Double-blind DISCREET Study. SKIN The Journal of Cutaneous Medicine, 7(2), s110. https://doi.org/10.25251/skin.7.supp.110
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Posters from 2023 WCH Dermatology Conference: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>